JP6356071B2 - 急性腎障害の診断および/または予後診断方法 - Google Patents
急性腎障害の診断および/または予後診断方法 Download PDFInfo
- Publication number
- JP6356071B2 JP6356071B2 JP2014546594A JP2014546594A JP6356071B2 JP 6356071 B2 JP6356071 B2 JP 6356071B2 JP 2014546594 A JP2014546594 A JP 2014546594A JP 2014546594 A JP2014546594 A JP 2014546594A JP 6356071 B2 JP6356071 B2 JP 6356071B2
- Authority
- JP
- Japan
- Prior art keywords
- mir
- expression
- expression level
- microrna
- diagnosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000009304 Acute Kidney Injury Diseases 0.000 title claims description 55
- 208000033626 Renal failure acute Diseases 0.000 title claims description 53
- 201000011040 acute kidney failure Diseases 0.000 title claims description 53
- 238000003745 diagnosis Methods 0.000 title description 35
- 238000004393 prognosis Methods 0.000 title description 8
- 239000002679 microRNA Substances 0.000 claims description 71
- 108091070501 miRNA Proteins 0.000 claims description 48
- 208000012998 acute renal failure Diseases 0.000 claims description 41
- 108700011259 MicroRNAs Proteins 0.000 claims description 26
- 210000002966 serum Anatomy 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 20
- 230000000302 ischemic effect Effects 0.000 claims description 17
- 239000000523 sample Substances 0.000 claims description 16
- 108091035155 miR-10a stem-loop Proteins 0.000 claims description 13
- 108091088477 miR-29a stem-loop Proteins 0.000 claims description 13
- 108091029716 miR-29a-1 stem-loop Proteins 0.000 claims description 13
- 108091092089 miR-29a-2 stem-loop Proteins 0.000 claims description 13
- 108091066559 miR-29a-3 stem-loop Proteins 0.000 claims description 13
- 108091032320 miR-146 stem-loop Proteins 0.000 claims description 12
- 108091024530 miR-146a stem-loop Proteins 0.000 claims description 12
- 108091083275 miR-26b stem-loop Proteins 0.000 claims description 12
- 108091044133 miR-454 stem-loop Proteins 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 108091032902 miR-93 stem-loop Proteins 0.000 claims description 7
- 230000007423 decrease Effects 0.000 claims description 6
- -1 miR-27a Proteins 0.000 claims description 5
- 238000003753 real-time PCR Methods 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 8
- 208000001647 Renal Insufficiency Diseases 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 201000006370 kidney failure Diseases 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 238000007675 cardiac surgery Methods 0.000 description 6
- 229940109239 creatinine Drugs 0.000 description 5
- 238000013211 curve analysis Methods 0.000 description 5
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000008085 renal dysfunction Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- 102000003661 Ribonuclease III Human genes 0.000 description 2
- 108010057163 Ribonuclease III Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000003589 nefrotoxic effect Effects 0.000 description 2
- 231100000381 nephrotoxic Toxicity 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011896 sensitive detection Methods 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 102000047351 Exportin-5 Human genes 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000847058 Homo sapiens Exportin-5 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102000013519 Lipocalin-2 Human genes 0.000 description 1
- 108010051335 Lipocalin-2 Proteins 0.000 description 1
- 108091093082 MiR-146 Proteins 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000019948 ion homeostasis Effects 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 238000006902 nitrogenation reaction Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000015909 regulation of biological process Effects 0.000 description 1
- 230000008663 renal system process Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013520 translational research Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
・血清クレアチニンなどの一般的臨床診断パラメーターにより示される最大腎障害時の虚血性病因を有する急性腎不全患者から得た2試料。
・血清クレアチニンによる再評価で腎機能が回復したときの腎不全後7または10日の同じ患者から得た2試料。
・腎毒性物質により生じた腎不全の患者から得た2試料。1つは最大損傷時、他の1つは腎機能回復時。
・最大腎損傷時に得た、敗血症による腎不全患者から得た試料。
・コントロールとして用いる5人の健康人からなる2群。
・虚血性病因を有する急性腎不全患者4人(PI1、PI2、PI3、PI4という)。各患者から得た0日(腎不全の診断時)、腎不全の診断後1、3、5および7日の試料を用いた。
・腎毒性物質により生じた急性腎不全の患者3人(PT1、PT2、PT3という)。各患者から得た0日(腎不全の診断時)、腎不全の診断後1、3、5および7日の試料を用いた。
・それぞれ10人の健常人からなる2コントロール群。
ARF患者のmiR-93発現(図6)は、健康コントロールに比べて低下し、何人かの患者で第7日のこのmiRNAがコントロールに近い値に回復する傾向を示したことにも注意すべきである。
表1:第0日におけるICUのARF患者のmiRNAに対するROC曲線分析。
表2.第7日におけるICUのARF患者のmiRNAに対するROC曲線分析
Claims (8)
- 対象から単離した血液または血清試料中の少なくともmiR−26bの発現レベルを測定し、該発現レベルをコントロール値と比較することを含む、対象において虚血性急性腎不全発現の素因を示すか否かを決定するための方法であって、該発現レベルの低下は虚血性急性腎不全発現の素因を示す、方法。
- 該方法が、対象から単離した血液または血清試料中のmiR−29a、miR−454、miR−146a、miR−27a、miR−93およびmiR−10aから選ばれる少なくとも1のミクロRNAの発現レベルを測定し、該発現レベルをコントロール値と比較することをさらに含み、該発現レベルの低下が虚血性急性腎不全発現の素因を示す、請求項1に記載の方法。
- 該方法が、対象から単離した血液または血清試料中のmiR−26bの発現レベルおよびmiR−29a、miR−454、miR−146a、miR−27a、miR−93およびmiR−10aから選ばれる少なくとも1のミクロRNAの発現レベルをまとめて測定し、該発現レベルをコントロール値と比較することを含み、該発現レベルの低下が虚血性急性腎不全発現の素因を示す、請求項1に記載の方法。
- ミクロRNAの発現をPCR法により測定する、請求項1〜3のいずれかに記載の方法。
- ミクロRNAの発現を定量的PCR法により測定する、請求項4に記載の方法。
- 請求項1〜5のいずれかに記載の方法によって対象において虚血性急性腎不全発現の素因を示すか否かを決定するための、キットであって、該キットは、血液または血清試料中の少なくともmiR−26bの発現レベルを測定するのに必要なプローブおよびプライマーを含む、キット。
- キットが、血液または血清試料中のmiR−29a、miR−454、miR−146a、miR−27a、miR−93およびmiR−10aからなる群から選ばれる少なくとも1のミクロRNAの発現レベルを測定するのに必要なプローブおよびプライマーをさらに含む、請求項6に記載のキット。
- キットが、血液または血清試料中のmiR−26bの発現レベルおよびmiR−29a、miR−454、miR−146a、miR−27a、miR−93およびmiR−10aからなる群から選ばれるミクロ−RNAの発現レベルをまとめて測定するのに必要なプローブおよびプライマーを含む、請求項6に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP201132023 | 2011-12-15 | ||
ES201132023A ES2414290B1 (es) | 2011-12-15 | 2011-12-15 | Metodo para el diagnóstico y/o pronóstico de daño renal agudo |
PCT/ES2012/070858 WO2013087961A1 (es) | 2011-12-15 | 2012-12-11 | Metodo para el diagnostico y/o pronostico de daño renal agudo |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015501650A JP2015501650A (ja) | 2015-01-19 |
JP6356071B2 true JP6356071B2 (ja) | 2018-07-11 |
Family
ID=48611890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014546594A Expired - Fee Related JP6356071B2 (ja) | 2011-12-15 | 2012-12-11 | 急性腎障害の診断および/または予後診断方法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20140378335A1 (ja) |
EP (1) | EP2792752B1 (ja) |
JP (1) | JP6356071B2 (ja) |
CN (2) | CN107385025A (ja) |
BR (1) | BR112014014279A2 (ja) |
CA (1) | CA2859081A1 (ja) |
ES (3) | ES2432853B1 (ja) |
MX (1) | MX359369B (ja) |
RU (1) | RU2657422C2 (ja) |
WO (1) | WO2013087961A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105303261A (zh) * | 2015-11-10 | 2016-02-03 | 北京大学第一医院 | 医院内急性肾损伤预警系统 |
JP7166659B2 (ja) * | 2018-10-04 | 2022-11-08 | 学校法人自治医科大学 | 急性腎障害の検査方法、急性腎障害の検査用キット、動物治療方法、及び急性腎障害用医薬 |
RU2749245C1 (ru) * | 2020-11-13 | 2021-06-07 | федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се | Способ диагностики гипоксии паренхимы почек при экспериментальной интраабдоминальной гипертензии |
RU2768578C1 (ru) * | 2020-12-25 | 2022-03-24 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ульяновский государственный университет" | Способ прогнозирования острого повреждения почек у пациентов с декомпенсацией хронической сердечной недостаточности на основе системы оценки риска |
ES2950308B2 (es) * | 2022-03-02 | 2024-06-19 | Univ Oviedo | Métodos y usos para cuantificar la sobredistensión pulmonar mediante la determinación de un conjunto de miARNs |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2198400C2 (ru) * | 2001-04-12 | 2003-02-10 | Российский НИИ геронтологии | Способ диагностики гипоксически-ишемического поражения почек |
CA2699646A1 (en) | 2007-09-14 | 2009-03-19 | The Ohio State University Research Foundation | Mirna expression in human peripheral blood microvesicles and uses thereof |
CN101988120A (zh) | 2009-07-30 | 2011-03-23 | 江苏命码生物科技有限公司 | 一种利用血清中的微小核糖核酸诊断肝癌的新技术 |
ES2363661B2 (es) * | 2009-09-04 | 2012-05-30 | Fundación Para La Investigación Biomédica Del Hospital Universitario Ramón Y Cajal. | Método para el diagnóstico y/o pronóstico de daño renal agudo. |
CN102218144B (zh) * | 2010-04-13 | 2016-03-02 | 江苏命码生物科技有限公司 | 一种调节生物体内微小核糖核酸含量的方法及其用途 |
SG184821A1 (en) * | 2010-04-21 | 2012-11-29 | Amc Amsterdam | Means and methods for determining risk of cardiovascular disease |
-
2011
- 2011-12-15 ES ES201232008A patent/ES2432853B1/es active Active
- 2011-12-15 ES ES201132023A patent/ES2414290B1/es active Active
-
2012
- 2012-12-11 EP EP12857270.8A patent/EP2792752B1/en active Active
- 2012-12-11 RU RU2014123753A patent/RU2657422C2/ru not_active IP Right Cessation
- 2012-12-11 WO PCT/ES2012/070858 patent/WO2013087961A1/es active Application Filing
- 2012-12-11 BR BR112014014279A patent/BR112014014279A2/pt not_active Application Discontinuation
- 2012-12-11 US US14/364,644 patent/US20140378335A1/en not_active Abandoned
- 2012-12-11 CA CA2859081A patent/CA2859081A1/en not_active Abandoned
- 2012-12-11 MX MX2014006811A patent/MX359369B/es active IP Right Grant
- 2012-12-11 JP JP2014546594A patent/JP6356071B2/ja not_active Expired - Fee Related
- 2012-12-11 ES ES12857270.8T patent/ES2676449T3/es active Active
- 2012-12-11 CN CN201710541520.7A patent/CN107385025A/zh active Pending
- 2012-12-11 CN CN201280061797.5A patent/CN104080925B/zh not_active Expired - Fee Related
-
2016
- 2016-09-27 US US15/277,734 patent/US20170175191A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR112014014279A8 (pt) | 2017-06-13 |
CN104080925A (zh) | 2014-10-01 |
ES2414290A2 (es) | 2013-07-18 |
RU2014123753A (ru) | 2016-02-10 |
EP2792752B1 (en) | 2018-04-04 |
RU2657422C2 (ru) | 2018-06-13 |
ES2414290B1 (es) | 2014-04-16 |
US20140378335A1 (en) | 2014-12-25 |
BR112014014279A2 (pt) | 2017-06-13 |
CN104080925B (zh) | 2017-08-01 |
CA2859081A1 (en) | 2013-06-20 |
EP2792752A1 (en) | 2014-10-22 |
ES2676449T3 (es) | 2018-07-19 |
MX2014006811A (es) | 2015-11-06 |
JP2015501650A (ja) | 2015-01-19 |
US20170175191A1 (en) | 2017-06-22 |
ES2432853B1 (es) | 2015-03-09 |
WO2013087961A1 (es) | 2013-06-20 |
EP2792752A4 (en) | 2015-12-02 |
ES2432853A2 (es) | 2013-12-05 |
CN107385025A (zh) | 2017-11-24 |
ES2432853R1 (es) | 2014-03-11 |
ES2414290R1 (es) | 2013-10-11 |
MX359369B (es) | 2018-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6203209B2 (ja) | 早期結腸直腸癌の検出のための血漿マイクロrna | |
JP6356071B2 (ja) | 急性腎障害の診断および/または予後診断方法 | |
US20140120545A1 (en) | METHODS OF USING miRNA FROM BODILY FLUIDS FOR EARLY DETECTION AND MONITORING OF MILD COGNITIVE IMPAIRMENT (MCI) AND ALZHEIMER'S DISEASE (AD) | |
JP2011510623A (ja) | 妊娠の合併症を診断するための方法及び組成物 | |
WO2010055488A2 (en) | Compositions and methods for micro-rna expession profiling of hepatocellular cancer | |
WO2016186987A1 (en) | Biomarker micrornas and method for determining tumor burden | |
US20120115150A1 (en) | miRNA BIOMARKERS FOR THE DIAGNOSIS OF DUCHENNE MUSCULAR DYSTROPHY, ITS PROGRESSION AND FOR MONITORING THERAPEUTIC INTERVENTIONS | |
CN111518884B (zh) | miRNA30簇作为阿尔茨海默病诊断标志物的应用 | |
TW201309805A (zh) | 預測大腸直腸癌復發的生物標記 | |
WO2020088704A1 (en) | Postpartum epigenetic profile of cardiovascular micrornas in women exposed to pregnancy-related complications | |
WO2009025790A1 (en) | Diagnostic and prognostic use of human bladder cancer-associated micro rnas | |
US20190390275A1 (en) | Chronic kidney disease diagnostic | |
KR101381894B1 (ko) | 위암의 림프절 전이 진단 마커로서의 혈청 miRNA | |
TW202223103A (zh) | 泛癌症早篩預測方法 | |
ES2432854B1 (es) | Metodo para el diagnóstico y/o pronóstico de daño renal agudo | |
CN105821131B (zh) | 骨肉瘤miRNA标记物 | |
ES2432849B1 (es) | Metodo para el diagnóstico y/o pronóstico de daño renal agudo | |
AU2021105761A4 (en) | Use of microRNA markers microRNA-130a and microRNA-130b in diagnosis of Hepatic fibrosis | |
CN108728528A (zh) | 基于Taqman探针的肾小管上皮细胞特异性基因检测荧光定量PCR一步法试剂盒 | |
CN118272516A (zh) | 尿液迁移体miRNA标志物及其应用、诊断原发性肾小球疾病的试剂盒 | |
ES2432533A1 (es) | Metodo para el diagnóstico y/o pronóstico de daño renal agudo | |
ES2434106A2 (es) | Metodo para el diagnóstico y/o pronóstico de daño renal agudo | |
CN111187836A (zh) | 泌尿上皮癌的检测套组及检测方法 | |
US20230295733A1 (en) | Marker consisting of plasma microrna and a new method for diagnosis of hepatocellular carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151202 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160218 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161018 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170321 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170704 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171003 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171225 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180515 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180613 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6356071 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |